Xiaojing Li

Dr. Xiaojing Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
CHChi Hou
Chi Hou
WWWenlin Wu
Wenlin Wu
YTYang Tian
Yang Tian
YZYani Zhang
Yani Zhang
HZHaixia Zhu
Haixia Zhu
WCWen-Xiong Chen
Wen-Xiong Chen

13 January 2024 in BMC Neurology
Verified
Journal Article
Open access
PDF file
KSKaili Shi
Kaili Shi
HZHuimin Zhao
Huimin Zhao
YLYing Li
Ying Li
XLXiaojing Li
Xiaojing Li
WCWen-Xiong Chen
Wen-Xiong Chen
There are very limited reports on anti-metabolic glutamate receptor5 (mGluR5) encephalitis, especially lacking of pediatric research. The disease was mostly accompanied by tumors, mainly Hodgkin's lymphoma. No reports of other tumors, such as gangliocytoma have been reported to associate with anti-mGluR5 encephalitis so far. We reported a case of a 12-year-old boy with anti-mGluR5 encephalitis complicated with gangliocytoma. The patient suffered from mental disorders including auditory hallucination, and sleep disorders. His cranial magnetic resonance imaging (MRI) showed an abnormality in the right insular lobe. Autoimmune encephalitis antibodies testing was positive for mGluR5 IgG antibody both in cerebrospinal fluid and serum (1:3.2, 1:100 respectively). Abdominal CT indicated a mass in left retroperitoneal confirmed with gangliocytoma via pathology. The patient underwent resection of gangliocytoma. After first-line immunotherapy (glucocorticoid, gamma globulin), his condition was improved. Furthermore, we provide a summary of 6 pediatric cases of Anti-mGluR5 encephalitis. Most of them complicated with Hodgkin's lymphoma, except the case currently reported comorbid with gangliocytoma. The curative effect is satisfactory. We report the first patient with anti-mGlur5 encephalitis complicated with gangliocytoma. It suggests that in addition to paying attention to the common lymphoma associated with anti-mGlur5 encephalitis, we should also screen the possibility of other tumors for early detection of the cause, active treatment and prevention of recurrence.

1 March 2022 in Brain
Verified
Journal Article
Open access
PDF file
BPBing-Wei Peng
Bing-Wei Peng
YTYang Tian
Yang Tian
LCLi Chen
Li Chen
LDLi-Fen Duan
Li-Fen Duan
XWXiu-Ying Wang
Xiu-Ying Wang
WCWen-Xiong Chen
Wen-Xiong Chen
We read with great interest the article recently published in Brain by Johannesen and colleagues,1 which revealed the clear genotype-phenotype correlations between the age at seizure onset, type of epilepsy and gain-of-function (GOF) or loss-of-function (LOF) effects of SCN8A variants. The authors collected the largest cohort of individuals with SCN8A-related epilepsy from a multi-country study and found that generalized epilepsy with absence seizures is the main epilepsy phenotype of LOF variant carriers and the extent of the electrophysiological dysfunction of the GOF variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Their pharmacological data indicated that sodium channel blockers (SCBs) present a treatment option in the SCN8A-related focal epilepsy with onset in the first year of life.1

17 October 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
XLXiaojing Li
Xiaojing Li
WWWenlin Wu
Wenlin Wu
YZYiru Zeng
Yiru Zeng
WWWenxiao Wu
Wenxiao Wu
CHChi Hou
Chi Hou
WCWen-Xiong Chen
Wen-Xiong Chen
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system. Relapse and incomplete recovery from relapse are common in NMOSD. Most patients with NMOSD have IgG to aquaporin-4 (AQP4-IgG). New biological agents for AQP4-IgG-seropositive NMOSD, such as satralizumab, have become available for maintenance therapy. Satralizumab is an anti-interleukin-6 receptor monoclonal antibody. To date, few studies have evaluated satralizumab as an add-on treatment in pediatric NMOSD patients. Here, we report an 11-year-old girl with NMOSD who frequently relapsed under long-term treatment, including oral prednisone, rituximab, mycophenolate mofetil (MMF), and maintenance intravenous immunoglobulin treatment even with B-cell depletion. For the poor treatment response and to improve the efficacy of relapse prevention further, the patient received satralizumab treatment as an add-on therapy to MMF plus oral prednisone, with a dose of 120 mg administered subcutaneously at weeks 0, 2, and 4 and every 4 weeks after that. After initiating satralizumab, the patient remained relapse-free for 14 months at the last follow-up. Satralizumab might be effective and safe as an add-on treatment in refractory pediatric AQP4-IgG-seropositive NMOSD under B-cell depletion.

8 October 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
HZHaixia Zhu
Haixia Zhu
WWWenlin Wu
Wenlin Wu
LCLianfeng Chen
Lianfeng Chen
CHChi Hou
Chi Hou
YZYiru Zeng
Yiru Zeng
XLXiaojing Li
Xiaojing Li
Objective: To study the clinical characteristics and treatment of pediatric opsoclonus-myoclonus syndrome (OMS).Methods: We analyzed the clinical data of nine children OMS between June 2017 and Nov 2020.Results: Nine children (M/F = 3:6, median onset age was 18 months) diagnosed with OMS were included in the study. Before onset, human rhinovirus and respiratory syncytial virus were seen in one patient, respectively. And one patient received Japanese encephalitis vaccination. Three patients had neuroblastoma, and one patient had ganglioneuroblastoma. All patients' symptoms were improved after receiving surgery (for four patients with tumor), intravenous human immunoglobulin and pulsed methylprednisolone. However, four patients without mass relapsed and became relapse free after rituximab treatment. The relapse rate was 44.4% (4/9). The OMS severity score at the last follow-up was significantly lower than the OMS severity score at onset (3.0 ± 1.0 vs. 11.0 ± 2.2, paired-samples t-test, P < 0.001). All patients had at least one item of neurological symptoms or neuropsychological disturbances.Conclusion: For pediatric OMS, human rhinovirus infection and respiratory syncytial virus infection can be seen before onset. Rituximab is effective in reducing relapse. Improving recognition and long-term prognosis in OMS is urgent.

26 June 2022 in Clinical Genetics
Verified
Journal Article
Closed access
YLYunting Lin
Yunting Lin
WZWen Zhang
Wen Zhang
DLDuan Li
Duan Li
XCXiaodan Chen
Xiaodan Chen
ZLZhikun Lu
Zhikun Lu
XLXiuzhen Li
Xiuzhen Li